Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.180
-0.070 (-5.60%)
At close: Dec 5, 2025, 4:00 PM EST
1.240
+0.060 (5.08%)
After-hours: Dec 5, 2025, 6:55 PM EST
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -67.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Citius Pharmaceuticals stock has a target of 6.00, which predicts an increase of 408.47% from the current stock price of 1.18.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Citius Pharmaceuticals stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Dec 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Aug 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +408.47% | Jun 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +408.47% | Jun 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +662.71% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
65.10M
EPS This Year
-3.30
from -5.97
EPS Next Year
0.37
from -3.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 82.2M | ||||
| Avg | n/a | 65.1M | ||||
| Low | n/a | 48.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.52 | 2.00 | ||||
| Avg | -3.30 | 0.37 | ||||
| Low | -3.96 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.